Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Beam Therapeutics (BEAM) Net Income towards Common Stockholders (2019 - 2025)

Historic Net Income towards Common Stockholders for Beam Therapeutics (BEAM) over the last 7 years, with Q3 2025 value amounting to -$112.7 million.

  • Beam Therapeutics' Net Income towards Common Stockholders fell 1661.36% to -$112.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$414.6 million, marking a year-over-year decrease of 18876.67%. This contributed to the annual value of -$376.7 million for FY2024, which is 18427.57% down from last year.
  • Beam Therapeutics' Net Income towards Common Stockholders amounted to -$112.7 million in Q3 2025, which was down 1661.36% from -$102.3 million recorded in Q2 2025.
  • Beam Therapeutics' 5-year Net Income towards Common Stockholders high stood at $142.8 million for Q4 2023, and its period low was -$201.6 million during Q1 2021.
  • Its 5-year average for Net Income towards Common Stockholders is -$78.6 million, with a median of -$91.1 million in 2024.
  • As far as peak fluctuations go, Beam Therapeutics' Net Income towards Common Stockholders plummeted by 53513.47% in 2021, and later skyrocketed by 47236.17% in 2023.
  • Over the past 5 years, Beam Therapeutics' Net Income towards Common Stockholders (Quarter) stood at -$64.7 million in 2021, then skyrocketed by 40.73% to -$38.3 million in 2022, then skyrocketed by 472.36% to $142.8 million in 2023, then crashed by 163.27% to -$90.4 million in 2024, then fell by 24.76% to -$112.7 million in 2025.
  • Its Net Income towards Common Stockholders stands at -$112.7 million for Q3 2025, versus -$102.3 million for Q2 2025 and -$109.3 million for Q1 2025.